中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
Chinese Journal of Woman and Child Health Research
2015年
5期
1018-1020
,共3页
B超%癌坯抗原125%鉴别诊断%卵巢恶性肿瘤%卵巢良性肿瘤
B超%癌坯抗原125%鑒彆診斷%卵巢噁性腫瘤%卵巢良性腫瘤
B초%암배항원125%감별진단%란소악성종류%란소량성종류
B ultrasound%cancer antigen 125 (CA125)%differential diagnosis%ovarian cancer%ovarian benign tumor
目的：评估B超检查结合血清癌坯抗原125（ CA125）检测在鉴别诊断妇女卵巢良、恶性肿瘤中的临床价值。方法对98例经过病理检查确诊的卵巢肿瘤患者的B超检查结果、血清CA125检查结果进行回顾性分析，其中包含47例恶性卵巢肿瘤患者、51例良性肿瘤患者。对两种方法联合诊断妇女卵巢良、恶性肿瘤的临床价值进行评估。结果在B超检查下，良、恶性卵巢肿瘤的大小差异无统计学意义（P＞0．05）；良、恶性卵巢肿瘤的质地、形状、位置、包膜在超声下表现差异均具有统计学意义（χ2值分别为17．814、7．500、5．226、25．246、均P＜0．05）。卵巢良性肿瘤的CA125值为21．74±12．15IU／mL，显著低于卵巢恶性肿瘤的254．20±189．40IU／mL，差异有统计学意义（t ＝8．395，P ＜0．05）。 B 超检查诊断卵巢恶性肿瘤的灵敏度为76．60％、特异度为76．47％、误诊率为23．53％、漏诊率为24．40％、Kappa＝0．530。 CA125检查诊断卵巢恶性肿瘤的灵敏度为68．09％、特异度为66．67％、误诊率为33．33％、漏诊率为31．91％、Kappa＝0．347。 B超联合CA125检查诊断卵巢恶性肿瘤的灵敏度为89．36％、特异度为84．31％、误诊率为15．69％、漏诊率为10．64％、Kappa＝0．735。结论 B超检查结合CA125可以显著的提高鉴别诊断卵巢良恶性肿瘤的临床价值。
目的：評估B超檢查結閤血清癌坯抗原125（ CA125）檢測在鑒彆診斷婦女卵巢良、噁性腫瘤中的臨床價值。方法對98例經過病理檢查確診的卵巢腫瘤患者的B超檢查結果、血清CA125檢查結果進行迴顧性分析，其中包含47例噁性卵巢腫瘤患者、51例良性腫瘤患者。對兩種方法聯閤診斷婦女卵巢良、噁性腫瘤的臨床價值進行評估。結果在B超檢查下，良、噁性卵巢腫瘤的大小差異無統計學意義（P＞0．05）；良、噁性卵巢腫瘤的質地、形狀、位置、包膜在超聲下錶現差異均具有統計學意義（χ2值分彆為17．814、7．500、5．226、25．246、均P＜0．05）。卵巢良性腫瘤的CA125值為21．74±12．15IU／mL，顯著低于卵巢噁性腫瘤的254．20±189．40IU／mL，差異有統計學意義（t ＝8．395，P ＜0．05）。 B 超檢查診斷卵巢噁性腫瘤的靈敏度為76．60％、特異度為76．47％、誤診率為23．53％、漏診率為24．40％、Kappa＝0．530。 CA125檢查診斷卵巢噁性腫瘤的靈敏度為68．09％、特異度為66．67％、誤診率為33．33％、漏診率為31．91％、Kappa＝0．347。 B超聯閤CA125檢查診斷卵巢噁性腫瘤的靈敏度為89．36％、特異度為84．31％、誤診率為15．69％、漏診率為10．64％、Kappa＝0．735。結論 B超檢查結閤CA125可以顯著的提高鑒彆診斷卵巢良噁性腫瘤的臨床價值。
목적：평고B초검사결합혈청암배항원125（ CA125）검측재감별진단부녀란소량、악성종류중적림상개치。방법대98례경과병리검사학진적란소종류환자적B초검사결과、혈청CA125검사결과진행회고성분석，기중포함47례악성란소종류환자、51례량성종류환자。대량충방법연합진단부녀란소량、악성종류적림상개치진행평고。결과재B초검사하，량、악성란소종류적대소차이무통계학의의（P＞0．05）；량、악성란소종류적질지、형상、위치、포막재초성하표현차이균구유통계학의의（χ2치분별위17．814、7．500、5．226、25．246、균P＜0．05）。란소량성종류적CA125치위21．74±12．15IU／mL，현저저우란소악성종류적254．20±189．40IU／mL，차이유통계학의의（t ＝8．395，P ＜0．05）。 B 초검사진단란소악성종류적령민도위76．60％、특이도위76．47％、오진솔위23．53％、루진솔위24．40％、Kappa＝0．530。 CA125검사진단란소악성종류적령민도위68．09％、특이도위66．67％、오진솔위33．33％、루진솔위31．91％、Kappa＝0．347。 B초연합CA125검사진단란소악성종류적령민도위89．36％、특이도위84．31％、오진솔위15．69％、루진솔위10．64％、Kappa＝0．735。결론 B초검사결합CA125가이현저적제고감별진단란소량악성종류적림상개치。
Objective To evaluate the clinical value of B ultrasound examination combined with serum cancer antigen 125 ( CA125 ) in differential diagnosis of malignant tumors from benign tumors.Methods Retrospective analysis was conducted on B ultrasound examination and serum CA125 detecting results of 98 cases of ovarian tumors confirmed by pathological examination, including 47 cases of malignant ovarian tumor and 51 cases of benign tumors.The clinical value of the combination of two methods in diagnosis of ovarian benign and malignant tumors was evaluated.Results B ultrasound examination showed that there was no significant difference in size of benign and malignant ovarian tumors (P>0.05), but the differences in texture, shape, location and capsule were significant (χ2 value was 17.814, 7.500, 5.226 and 25.246, respectively, all P<0.05).CA125 level of benign ovarian tumors was 21.74 ±12.15IU/mL, which was significantly lower than that of ovarian cancer (254.20 ±189.40IU/mL), and the difference was statistically significant (t=8.395, P<0.05).With B ultrasound examination, the sensitivity, specificity, misdiagnosis rate and rate of missed diagnosis was 76.60%, 76.47%, 23.53% and 24.40%, respectively with Kappa of 0.530, while they were 68.09%, 66.67%, 33.33% and 31.91%, respectively with Kappa of 0.347 with CA125.When combining two methods, they were 89.36%, 84.31%, 15.69% and 10.64%, respectively with Kappa of 0.735.Conclusion Serum CA125 combined with B ultrasound examination can significantly improve the differential diagnosis of benign and malignant ovarian tumors.
